KLOW Peptide Blend: Composition and What the Research Shows

Research summary. KLOW is a four-component peptide blend. As stocked by Nox Amino it is 80mg total: GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg. It is the GLOW composition with KPV added. Each constituent has its own published literature, summarized below in past-tense research voice. No published study has evaluated the four-component combination itself. KLOW is a reference material characterized by identity and purity, not a consumer product.

Author: Nox Amino Research Team Reviewed by: the Nox Amino Research Team Published: July 16, 2026 · Updated: July 16, 2026 Editorial methodology: /learn/editorial-standards

Research Use Only (RUO). All materials referenced on this page are intended exclusively for laboratory research and analytical use. They are not drugs, cosmetics, dietary supplements, or articles for human or veterinary consumption, and nothing here constitutes medical advice, a cosmetic claim, or a recommendation for use in or on the body. This page describes composition and cites published third-party studies in their own terms. It contains no protocol, no preparation guidance, and no claims about outcomes for any reader. See our Certificates of Analysis for identity and purity data on individually stocked reference materials; no COA is published for this blend.

What is in KLOW

KLOW is a name used across the research-compound market for a four-peptide blend. Blend naming is not standardized, so the only composition that can be stated with confidence is that of a specific item from a specific supplier. The Nox Amino KLOW reference material is 80mg total:

Constituent	Amount	What it is (per published literature)
GHK-Cu	50mg	Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine
BPC-157	10mg	15-amino-acid pentadecapeptide described as derived from a gastric-juice protein
TB-500	10mg	7-residue fragment (LKKTETQ) of the actin-sequestering peptide thymosin beta-4
KPV	10mg	Lysine-proline-valine tripeptide; C-terminal fragment of alpha-MSH
Total	80mg	Product page: /shop/klow

No Certificate of Analysis is currently published for the KLOW blend. Nox Amino publishes batch-specific COAs for individually stocked reference materials on the /coas page, but KLOW is not among them. If per-constituent analytical documentation is a requirement for your work, source the individual reference materials, which do carry published lot reports.

KLOW vs GLOW: one constituent apart

The two blends are identical except for KPV:

Blend	GHK-Cu	BPC-157	TB-500	KPV	Total
GLOW	50mg	10mg	10mg	none	70mg
KLOW	50mg	10mg	10mg	10mg	80mg

Composition is the only difference that can be stated from evidence. Whether adding a fourth characterized peptide to a lot changes anything biologically is not something the published literature addresses, for the reason in the next section.

The most important finding: the blend itself is unstudied

This is the part most pages about KLOW leave out, so it is worth stating plainly.

As of July 2026, PubMed searches combining these constituents return only broad review articles that discuss the compounds separately inside wider surveys of peptide research, such as a 2026 Sports Medicine review of approved and unapproved peptide therapies (PMID 41966639) and a 2026 Frontiers in Aging review (PMID 42021992). No indexed study evaluates the four-component combination as a blend, and no trial of it is registered on ClinicalTrials.gov.

So everything below describes each constituent studied on its own, largely in cell-culture or animal models. Claims about what four peptides do in combination are not supported by published evidence, and this page does not make them.

What the research reports, constituent by constituent

GHK-Cu (50mg). The largest constituent by mass, and the copper complex of glycyl-L-histidyl-L-lysine. Pickart and colleagues reported that "GHK-Cu at a very low, nontoxic concentration (1-10 nanomolar) stimulated both synthesis and breakdown of collagen" in research models (Pickart et al., BioMed Res Int 2015; PMID 26236730), and a 2018 review described GHK as capable of up- and down-regulating a large number of human genes (Pickart & Margolina, Int J Mol Sci 2018; PMID 29986520). Controlled human data is thin and mixed: a 2006 randomized topical study reported no statistically significant difference versus control (Miller et al., Arch Facial Plast Surg 2006; PMID 16847171). Fuller treatment: GHK-Cu copper-peptide research.

BPC-157 (10mg). A stable gastric pentadecapeptide. Chang and colleagues reported increased phosphorylation of FAK and paxillin in cultured tendon fibroblasts (Chang et al., J Appl Physiol 2011; PMID 21030672). A 2025 systematic review across 36 studies reported the literature was almost entirely preclinical and that no clinical safety data were found (Vasireddi et al., HSS J 2025; PMID 40756949).

TB-500 (10mg). A 7-residue fragment (LKKTETQ) of thymosin beta-4, which a 2004 Nature report characterized as a "G-actin sequestering peptide" (Bock-Marquette et al., Nature 2004; PMID 15565145). Side-by-side treatment: BPC-157 vs TB-500.

KPV (10mg). The constituent that distinguishes KLOW from GLOW. KPV corresponds to residues 11 to 13 of alpha-melanocyte-stimulating hormone (PubChem CID 125672). Dalmasso and colleagues reported that "nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase" in intestinal epithelial cells, with uptake mediated by the PepT1 transporter (Dalmasso et al., Gastroenterology 2008; PMID 18061177). Getting and colleagues reported that "KPV is unlikely to mediate its effects through melanocortin receptors" (Getting et al., J Pharmacol Exp Ther 2003; PMID 12750433). There are no controlled human studies of KPV. Fuller treatment: KPV peptide research.

What a blend does and does not tell you analytically

The practical reason blends exist is analytical convenience: four characterized reference materials presented as a single lot rather than four. That is a supply-format question, not a scientific one, and it carries a real tradeoff.

A blend is harder to characterize per-constituent than four separate vials, and per-constituent identity and purity are precisely what a Certificate of Analysis documents. Researchers who need per-constituent analytical certainty generally work from individual reference materials, whose lot reports are published on our /coas page. How to read those reports, including what HPLC purity and mass-spec identity actually establish, is covered in how to read a peptide COA.

Sourcing KLOW

To view KLOW, see the product detail page at /shop/klow, or browse the full catalog at /shop. As noted above, there is no published Certificate of Analysis for the blend itself.

Individually stocked reference materials do carry published batch reports, which are listed on the /coas page.

Create a free account to access published batch reports for individually stocked reference materials and see member pricing. → Create your account

This article cites third-party research and registry records for informational and laboratory-research purposes only. Nox Amino sells research compounds intended for laboratory and analytical use only, not for human or animal consumption. Nothing on this page is medical advice, a cosmetic claim, or a recommendation for any use in or on the body. Editorial methodology and review process: /learn/editorial-standards.

Frequently Asked Questions

What is in the KLOW peptide blend?

KLOW is a four-component blend. The Nox Amino KLOW reference material is 80mg total, composed of GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg. It is the GLOW composition with KPV added. As stocked by Nox Amino, KLOW is a reference material for laboratory research use only, characterized by identity and purity rather than by any effect in a person.

What is the difference between KLOW and GLOW?

KLOW is GLOW plus KPV. The Nox Amino GLOW reference material is 70mg total (GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg). KLOW is 80mg total and adds KPV 10mg to that same composition. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (lysine-proline-valine), which the published literature describes as inhibiting NF-kB signaling in cell and animal models.

Has any published study evaluated the KLOW blend itself?

No. As of July 2026, PubMed searches combining these constituents return only broad review articles that discuss the compounds separately within wider surveys of peptide research. No indexed study evaluates the four-component combination as a blend, and no clinical trial of it is registered on ClinicalTrials.gov. All published literature described on this page concerns each constituent studied on its own, and the majority of it is in vitro or animal work.

What does KPV add to the KLOW composition?

KPV is the constituent that distinguishes KLOW from GLOW, at 10mg. It is a lysine-proline-valine tripeptide corresponding to residues 11 to 13 of alpha-melanocyte-stimulating hormone (PubChem CID 125672). Dalmasso et al. (Gastroenterology 2008, PMID 18061177) reported that nanomolar concentrations of KPV inhibited NF-kB and MAP kinase activation in intestinal epithelial cells, with uptake mediated by the PepT1 transporter. There are no controlled human studies of KPV. This describes a distinct research literature, not an additive effect within a blend.

Is there a COA for the KLOW blend?

No. Nox Amino does not currently publish a Certificate of Analysis for the KLOW blend. Batch-specific COAs are published on the /coas page for individually stocked reference materials, but KLOW is not among them. A COA documents identity and purity for a specific lot, typically using mass spectrometry for identity and HPLC for purity, so a COA for a separately stocked single compound is not analytical documentation of the blend. If per-constituent analytical documentation is a requirement for your work, source the individual reference materials, which do carry published lot reports.